TGFB1 and neoplasm: They also found that TGF-β-blocking antibodies and anti-PD-L1 therapy reduced the transduction of TGF-β signaling in stromal cells and improved the infiltration level of T cells into the center of the tumor, thereby stimulating a strong antitumor immune response and causing tumor regression (Tauriello et al., 2018).